BMC Gastroenterology最新文献

{"title":"Prospective randomized, placebo-controlled study: role of branched-chain amino acids infusion as adjunct therapy post-liver surgery for patients in the intensive care unit.","authors":"Eman Ibrahim El-Desoki Mahmoud, Faten Farid Awdallah","doi":"10.1186/s12876-025-03696-3","DOIUrl":"10.1186/s12876-025-03696-3","url":null,"abstract":"<p><strong>Background and aim: </strong>Several animal studies have shown that Branched-chain amino acids (BCAAs) may prevent acute liver injury, although its effects in humans are as yet undetermined. Thus the purpose of this study is to evaluate the impact of intravenous BCAAs infusion on liver profile post-liver surgery in the intensive care unit (ICU).</p><p><strong>Methods: </strong>A randomized study that was applied for post liver surgery patients who were randomly allocated to receive either intravenous BCAA immediately post-operative or placebo.</p><p><strong>Measurements: </strong>Follow-up liver profile, Child-Pugh, and SOFA scores during the first week post-surgery.</p><p><strong>Main results: </strong>A significant decline of bilirubin and ALT on day three and five in the BCAA group compared to the control group respectively. There was a significant improvement of PT on day seven 12.5 in the BCAA group versus 12.9 in the control group, p-value 0.01. Total bilirubin levels decreased by 75% in the BCAA group, whereas in the control group saw an increase of 6.25% from the baseline which was statistically significant, p-value 0.0376. SOFA score was markedly improved in the BCAA group (p-value 0.013). In addition to a significantly shorter ICU stay in the BCAA group than in the control group (p-value 0.018).</p><p><strong>Conclusion: </strong>There are beneficial effects of BCAAs infusion post-liver surgery; including improved metabolic profile (liver function tests), and shorter ICU stay.</p><p><strong>Trial registration: </strong>(Clinicaltrials.gov registration number:NCT03448848), 28/02/2018.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"439"},"PeriodicalIF":2.5,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The disease course in microscopic colitis may be influenced by hormonal factors.","authors":"Klas Sjöberg, Lina Vigren, Marie-Rose Mellander, Izabella Janczewska, Hans Strid, Elisabeth Hultgren Hörnquist, Andreas Münch","doi":"10.1186/s12876-025-04083-8","DOIUrl":"10.1186/s12876-025-04083-8","url":null,"abstract":"<p><strong>Background: </strong>Microscopic colitis (MC) is characterized by non-bloody, watery diarrhea predominantly in elderly women. Known risk factors are smoking, medication with NSAIDs, PPIs or SSRIs, while data on hormonal factors is sparse. The aim of the present study was to investigate whether hormonal factors that disrupt the sex hormonal balance could have an impact on the disease course in MC.</p><p><strong>Methods: </strong>A questionnaire was distributed to 384 women with microscopic colitis (MC) (mean age 64 years, range 35-90) from five centers in Sweden about demographic aspects including age at diagnosis, disease duration, treatment, and polycystic ovary syndrome, endometriosis, bilateral oophorectomy, previous or ongoing medication with hormones or in vitro fertilization (IVF) in relation to the disease course.</p><p><strong>Results: </strong>The association with smoking could be verified. In relation to the disease course the odds ratio (OR) was higher for celiac disease and oral contraceptives but lower for hormone replacement therapy but for the two latter non-significant. However, bilateral oophorectomy had a significantly lower OR (0.41, CI 0.19-0.86, p = 0.019). No other factors had any substantial impact on the disease course.</p><p><strong>Conclusion: </strong>An association was verified with smoking. Celiac disease may be associated with more active disease. The observed lower OR for more active disease after bilateral oophorectomy is in line with a previously suggested association between the risk of MC and the hormonal balance. The exact mechanisms behind the hormonal effect on the disease course found in the present study are although still obscure.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"438"},"PeriodicalIF":2.5,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ZBTB10 as a potential prognosis biomarker and correlates with the tumor immune microenvironment in stomach adenocarcinoma.","authors":"Yingdi Jiang, Fuhua Han, Lu Dai, Shali Qiu, Yanjie Zhou, Ke Wang, Jiang Lin","doi":"10.1186/s12876-025-04047-y","DOIUrl":"10.1186/s12876-025-04047-y","url":null,"abstract":"<p><strong>Background: </strong>ZBTB10 is a member of the zinc finger and bric-a-brac/tramtrack/broad (ZBTB) domain-containing protein family, reported to be associated with tumorigenesis and progression. However, its specific roles in oncogenesis, prognosis, and immune infiltration in stomach adenocarcinoma (STAD) remain to be elucidated.</p><p><strong>Methods: </strong>We analyzed ZBTB10 mRNA and protein expression profiling in STAD tissues using various bioinformatics tools, including TIMER2, GEO, Human Protein Atlas (HPA) databases, and R software. Survival analysis was performed through the Kaplan-Meier plotter. UALCAN and TCGA databases were used to evaluate the association of ZBTB10 expression with clinicopathological characteristics. Genetic alterations of ZBTB10 in human tumor samples were analyzed using the cBioPortal database. The correlation between ZBTB10 expression and immune cell infiltration was assessed using the TISIDB and CIBERSORT algorithms. Gene Set Enrichment Analysis (GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway were applied to investigate the potential mechanism of ZBTB10 in STAD. Additionally, in vitro assays such as CCK-8, colony formation, and wound healing assays were performed to determine the biological role of ZBTB10 in STAD cells. Multiple immunohistochemistry (mIHC) was applied to characterize the association between immune cell infiltration and ZBTB10 expression in STAD tumor tissues.</p><p><strong>Results: </strong>Overall, ZBTB10 was differentially expressed in STAD compared to adjacent normal tissues, and higher ZBTB10 expression correlated with poorer overall survival (OS). Furthermore, GSEA and KEGG analysis suggested that ZBTB10 was predominantly involved in focal adhesion, PI3K-Akt signaling, and MAPK signaling pathways, suggesting its potential role in promoting tumor growth and progression. Moreover, based on the CIBERSORT algorithm, the expression of ZBTB10 was positively related to the levels of B cells, CD4 + T cells, M1 macrophages, and neutrophil cells. Meanwhile, ZBTB10 expression appeared to be negatively associated with tumor mutation burden (TMB) and microsatellite instability (MSI) in STAD, both of which influenced the efficacy of tumor immunotherapy. In vitro experiments demonstrated that ZBTB10 knockdown significantly inhibited tumor cell proliferation and invasion, and organoid area in STAD cell lines. The immune cell signature of CD45 was more prevalent with ZBTB10 expression in tumor tissue sections compared to adjacent normal tissues from STAD patients.</p><p><strong>Conclusions: </strong>Upregulated ZBTB10 is significantly correlated with poor survival outcomes and immune infiltration in STAD, revealing that ZBTB10 may serve as a promising prognostic biomarker and a potential target for immunotherapy in STAD.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"435"},"PeriodicalIF":2.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment sequences, outcomes, healthcare utilization, and costs in patients with inflammatory bowel diseases requiring advanced treatment-real world comparative effectiveness from German claims data.","authors":"Axel Dignass, Niels Teich, Stephan Kaiser, Juliane Sünwoldt, Christina Dünweber, Ines Weinhold, Julia Borchert, Robert Kudernatsch","doi":"10.1186/s12876-025-04022-7","DOIUrl":"10.1186/s12876-025-04022-7","url":null,"abstract":"<p><strong>Background: </strong>There is limited data on inflammatory bowel disease advanced therapy sequences. Therefore, we examined real-world advanced therapy sequences to compare persistence, healthcare use and costs in first-line advanced therapy.</p><p><strong>Methods: </strong>Evaluable patient characteristics, treatments, sequences, and outcomes were extracted from the WIG2 claims benchmark database and observed from 2014 to 2021. Therapeutic effectiveness (persistence without discontinuation or inadequate response), healthcare resource utilization, and associated costs were analyzed. Advanced treatment group differences were adjusted by inverse probability weighting.</p><p><strong>Results: </strong>Two thousand nine hundred forty-eight patients with Crohn's disease or ulcerative colitis initiated at least one of the following advanced therapies during the study period: adalimumab (1,260), golimumab (111), infliximab (1,035), tofacitinib (17), ustekinumab (138) or vedolizumab (387). In patients with ulcerative colitis, vedolizumab as first-line advanced therapy demonstrated superior effectiveness in persistence without inadequate response over three years compared to infliximab (p < 0.05). Patients taking infliximab or ustekinumab had higher disease-related costs than those taking adalimumab, golimumab, tofacitinib or vedolizumab. In Crohn's disease patients, first-line treatment with adalimumab (p < 0.001), ustekinumab (p < 0.001) and vedolizumab (p < 0.017), showed superior persistence over 3 years compared to infliximab, and time to inadequate response was longer in patients taking adalimumab and vedolizumab (p < 0.001). Disease-specific treatment costs were lower in patients receiving adalimumab or vedolizumab as first-line advanced therapy. Compared to infliximab, patients treated with ustekinumab had significantly higher costs.</p><p><strong>Conclusions: </strong>Anti-TNF agents were most frequently used in first-line advanced therapy; however, vedolizumab appeared to be a preferred choice in terms of persistence and cost measures over three years from the start of treatment.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"436"},"PeriodicalIF":2.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of platelet-to-lymphocyte ratio in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.","authors":"Qingtian Zhou, Zewen Jiang, Tingting Ye, Li Yu, Qinglian Wang, Pin Lin, Yanfeng Shao","doi":"10.1186/s12876-025-04028-1","DOIUrl":"10.1186/s12876-025-04028-1","url":null,"abstract":"<p><strong>Background: </strong>The prognostic significance of the Platelet-to-Lymphocyte Ratio (PLR) in patients with hepatocellular carcinoma (HCC) undergoing treatment with immune checkpoint inhibitors (ICIs) remains uncertain. A systematic review and meta-analysis was conducted to assess the prognostic value of PLR in HCC patients receiving ICIs.</p><p><strong>Methods: </strong>Potential eligible studies that explored the role of pretreatment PLR in HCC patients received ICIs treatment were retrieved using PubMed, Embase, and the Cochrane Library databases up to March 31, 2024. The Newcastle-Ottawa Scale was used to assess the study quality. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were utilized to investigate the correlation between PLR and both overall survival (OS) and progression-free survival (PFS). Subgroup analysis along with assessments for publication bias and sensitivity were performed to identify any sources of heterogeneity and to confirm the reliability of the pooled outcomes.</p><p><strong>Results: </strong>A total of 15 studies were analyzed, with the aggregate findings showing that elevated PLR levels were associated with poorer OS (HR: 1.79, 95%CI: 1.44-2.22, P < 0.001) and PFS (HR: 1.80, 95%CI: 1.40-2.30, P < 0.001) in HCC patients treated with ICIs. Moreover, the subgroup analyses did not alter the direction of results for OS and PFS. Publication bias and sensitivity analysis revealed that there was no significant publication bias among the articles and the pooled results were robust.</p><p><strong>Conclusion: </strong>These results show that elevated PLR is related to worse survival in patients with HCC treated with ICIs. PLR may therefore represent an effective indicator of prognosis in HCC undergoing ICIs treatment.</p><p><strong>Trial registration: </strong>This study is registered with the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY202450079).</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"437"},"PeriodicalIF":2.5,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of kinetochore component NDC80 promotes esophageal squamous cell carcinoma cells proliferation and migration.","authors":"Youwu Shi, Jing Sun, Feng Du, Zhiwei Sun, Ying Yang, Jing Yu, Yanjie Xiao, Xiaoyu Sun, Wen Zhang, Hongkun Zheng, Xiaodong Zhang, Jun Jia","doi":"10.1186/s12876-025-04048-x","DOIUrl":"10.1186/s12876-025-04048-x","url":null,"abstract":"<p><strong>Background: </strong>NDC80, a crucial component of the kinetochore, plays a pivotal role in regulating cell mitosis. Recent studies reported that NDC80 regulates the proliferation of cancer cells and may be related to poor prognosis in cancer. However, the biological function and mechanism of NDC80 in esophageal squamous cell carcinoma (ESCC) have not yet been elucidated. In this study, we analyzed the expression and mutation of NDC80 in ESCC tissue and assessed its impact on ESCC cells in vitro.</p><p><strong>Methods: </strong>A total of 52 ESCC tissues samples were collected and NDC80 gene status was analyzed by whole exome sequence. shRNA was used to knockdown NDC80 expression in two ESCC cell lines TE1 and ECA109 by targeting silence NDC80 gene. Cellular proliferation, apoptosis, migration, and invasion were examined.</p><p><strong>Results: </strong>Copy number variants (CNVs) of NDC80 were detected in 40.4% (21/52) cancer tissues. Genes with local CNVs values greater than 0.3 were classified as \"gain\". 23.1% (12/52) of cases showed CNVs gain and 58.3% (7/12) of which with genotype of AAB. Compared with patients of other NDC80 CNVs status, CNVs gain patients had relatively shorter overall survival, however with no statistic difference (19.9 ± 0.8 months vs. 30.9 ± 5.1 months, p = 0.124). Single nucleotide polymorphism mutation of NDC80 was detected in only 5.8% (3/52) cancer tissues including two previous reported mutation rs2271754 and rs6506019, and one novel SNP of C/A-T/G in 2,577,492, GRCh38.p13 intron variant in one case. The knockdown of NDC80 in vitro assays significantly suppressed cellular proliferation and induced increased apoptosis in both TE1 and ECA109 cells. Furthermore, the migration and invasion ability of both TE1 and ECA109 cells were also attenuated upon knockdown of NDC80.</p><p><strong>Conclusion: </strong>CNVs were identified as the predominant genetic variation of NDC80 gene in ESCC patients. In vitro assays suggested that NDC80 was not only involved into proliferation and apoptosis but also migration and invasion of ESCC cells.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"433"},"PeriodicalIF":2.5,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive evaluation of clinical phenotypes and pathogenic features in late-onset monogenic inflammatory bowel disease: a comparative study with infantile-onset cases.","authors":"Haoying Liu, Yinxian Shen, Jiaxin Xu, Shangzhan Huang, TingTing Qin, Qi Zhou, Jiazhi Liao, Fang Xiao","doi":"10.1186/s12876-025-04041-4","DOIUrl":"10.1186/s12876-025-04041-4","url":null,"abstract":"<p><strong>Background: </strong>Monogenic inflammatory bowel disease (mIBD) in patients with onset after the age of 16 has been increasingly recognized, but these reports are sporadic and lack a systematic overview, leaving the clinical and genetic characteristics poorly understood. This study aimed to characterize these late-onset mIBD (LO-mIBD), using an infantile-onset population as a control.</p><p><strong>Methods: </strong>Data were extracted from eligible case reports, case series, and cohorts published between January 1990 and October 2023. A comprehensive search of PubMed and Web of Science was conducted following PRISMA guidelines. Demographic, genetic, phenotypic, and genotypic data were collected for the comparative analysis between LO-mIBD (> 16 years) and infantile-onset mIBD (IO-mIBD, < 2 years) cases that met the inclusion criteria.</p><p><strong>Results: </strong>A total of 436 IO-mIBD and 110 LO-mIBD cases were included in the analysis. Patients with LO-mIBD had significantly lower rates of parental consanguinity and a higher frequency of heterozygous mutations in autosomal dominant genes compared with IO-mIBD cases. Meanwhile, patients with LO-mIBD more commonly presented with Crohn's disease (CD)-like gastrointestinal phenotypes. They exhibited markedly higher rates of intestinal ulcers, strictures, small intestinal involvement, and granulomatous pathology but fewer instances of villous atrophy, perianal disease, oral lesions, recurrent infections, and fever compared with IO-mIBD cases. The genes most commonly implicated in LO-mIBD were SLCO2A1, GUCY2C, CTLA4, CYBB, and SLC26A3. Defects affecting intestinal epithelial function and phagocytic activity were more prominent in LO-mIBD than in IO-mIBD.</p><p><strong>Conclusions: </strong>Patients with LO-mIBD exhibited diverse intestinal phenotypes dominated by CD-like disease, with gene defects predominantly involving epithelial and phagocytic functions. Genetic counseling, genotype-phenotype mapping, and functional validation of key pathways are critical for further improving the clinical management of patients with LO-mIBD.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"432"},"PeriodicalIF":2.5,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12139175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A study on the timing of small-bowel capsule endoscopy and its impact on the detection rate of bleeding sources.","authors":"Daisuke Kametaka, Masaya Iwamuro, Toshihiro Inokuchi, Seiji Kawano, Sakiko Hiraoka, Motoyuki Otsuka","doi":"10.1186/s12876-025-04044-1","DOIUrl":"10.1186/s12876-025-04044-1","url":null,"abstract":"","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"434"},"PeriodicalIF":2.5,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A risk prediction model for nausea and vomiting after TACE: a cross-sectional study.","authors":"Yali Dai, Mengting Zeng, Hong He, Miao Cai","doi":"10.1186/s12876-025-03934-8","DOIUrl":"10.1186/s12876-025-03934-8","url":null,"abstract":"<p><strong>Purpose: </strong>It was found that 33.8-52.5% of patients experienced nausea and vomiting after Transcatheter Arterial Chemoembolization (TACE) for liver cancer, based on prior literature. But there are no models that predict this risk. In this study, we investigated the factors associated with nausea and vomiting after TACE and developed a predictive model to predict these adverse events.</p><p><strong>Method: </strong>The study will include 401 patients who will be randomly assigned to the training group and validation group in a 7:3 ratio. An analysis of logistic regression was used to identify predictors and build a risk prediction model. Model performance was evaluated using the Area Under Curve (AUC), Calibration Curve, and Decision Curve Analysis (DCA).</p><p><strong>Results: </strong>This study ultimately included 401 patients for TACE, of whom 132(32.92%) patients experienced nausea and vomiting. Multivariate analysis identified five independent risk predictors: history of vomiting, prophylactic use of antiemetics, postoperative pain, platinum, and anthracycline. The training group had an AUC of 0.839, and the validation group had an AUC of 0.742. They had calibration curves with P = 0.208 and P = 0.482, respectively. The DCA curves showed that the model had good clinical benefit at threshold probabilities greater than 20%.</p><p><strong>Conclusion: </strong>A predictive model of nausea and vomiting after TACE has been developed, based on the individual risk factors, surgical factors and chemotherapy drug factors, with satisfactory predictive ability. This model can identify patients for TACE who are at high risk of nausea and vomiting. Our study provides an empirical basis for early detection, early diagnosis and early intervention of patients for TACE at high risk of nausea and vomiting.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"427"},"PeriodicalIF":2.5,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The potential value of serum pepsinogen and gastrin-17 for the diagnosis of chronic atrophic gastritis at different stages of severity: a clinical diagnostic study.","authors":"Tianyi Zhang, Xuyun Zhou, Xiangxiang Meng, Jianxin Li, Sujun Hou, Junmei Wang, Mengmeng Yin, Long Cao, Baitian Wang","doi":"10.1186/s12876-025-03996-8","DOIUrl":"10.1186/s12876-025-03996-8","url":null,"abstract":"<p><strong>Background: </strong>Pepsinogen (PG) and gastrin-17 (G-17) are crucial in the gastric digestive processes. This study aimed to assess the diagnostic value of the serum PG and G-17 in identifying chronic atrophic gastritis (CAG) at different stages of severity under varying Helicobacter pylori (H. pylori) infection statuses.</p><p><strong>Methods: </strong>We enrolled 300 participants from August 2023 to May 2024. All participants underwent gastroscopy with biopsy, and blood samples were taken for pepsinogen I (PGI), pepsinogen II (PGII), G-17, and H. pylori tests. The differences in G-17 and PG-related parameters were analyzed across groups, taking H. pylori infection status into account. The diagnostic performance of these markers was then evaluated both individually and in combination to distinguish CAG stages of severity. Statistical analysis was performed using SPSS statistical software.</p><p><strong>Results: </strong>According to pathological results, patients were divided into the non-atrophic gastritis group (NAG, n = 179), the mild atrophic gastritis group (MAG, n = 62), and the moderate and severe atrophic gastritis group (MSAG, n = 59). In the same pathological groups (NAG, MAG, and MSAG), PGII levels were higher in the H. pylori-positive subgroup, while the PGI/PGII ratio (PGR) was lower (p < 0.05). Serum PGII and G-17 levels increased with the pathological severity of the mucosa (p < 0.001, r = 0.364 and p < 0.001, r = 0.304, respectively), while PGR levels decreased with mucosal deterioration (p < 0.001, r = -0.407). Combination of PGI, PGII, PGR, and G-17 showed an area under the curve (AUC) of 0.723 (95% CI: 0.662-0.784), with a sensitivity of 65.29% and a specificity of 73.18% for detecting the presence of any CAG. For progressive CAG, which was defined by MSAG and classified into stages II-IV according to the Operative Link on Gastritis Assessment (OLGA) system, the AUC was 0.759 (95% CI: 0.683-0.836), with a sensitivity of 66.10% and a specificity of 83.40%, demonstrating the potential for even higher diagnostic ability. Among all the H. pylori-positive cohorts, PGII exhibited a higher AUC compared to the combined diagnostic approach using PGI, PGII, PGR, and G-17 (CAG: 0.656 vs. 0.654, MAG: 0.589 vs. 0.571, MSAG: 0.707 vs. 0.706, respectively).</p><p><strong>Conclusion: </strong>Serum PG and G-17 show potential in identifying CAG and MSAG. However, their diagnostic accuracy for MAG remains limited and would be better used as adjunctive indicators in conjunction with endoscopic examination. Further validation in larger, multi-center studies is needed to assess their utility in clinical practice.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"428"},"PeriodicalIF":2.5,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135244/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}